Rheumatoid Arthritis
Conditions
Brief summary
This prospective, multicenter, observational study will evaluate the use of concomitant glucocorticoid therapy in adults with rheumatoid arthritis (RA) being treated with tocilizumab in daily clinical practice. Participants will be observed for up to 52 weeks after starting treatment with tocilizumab. All visits and assessments will be performed as per routine clinical practice, with no study-specific visits or interventions.
Interventions
DRUGTocilizumab
For intravenous (IV) tocilizumab, the recommended dosage is 8 milligrams per kilogram (mg/kg) once every 4 weeks. For subcutaneous (SC) tocilizumab, the recommended dosage is 162 milligrams (mg) once weekly. However, because of the observational nature of the study, dosing and treatment duration is at the discretion of the physician in accordance with local clinical practice and local labeling.
DRUGGlucocorticoid Agent
Because of the observational nature of the study, the choice of glucocorticoid agent, as well as dosing and treatment duration, is at the discretion of the physician in accordance with local clinical practice and local labeling.
Sponsors
Hoffmann-La Roche
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of moderate to severe RA, defined as DAS28 greater than or equal to 3.7 * Naive to tocilizumab, or received tocilizumab within 8 weeks prior to enrollment * Physician has made decision to commence IV or SC tocilizumab in accordance with label and reimbursement criteria * Treated with glucocorticoids for RA when starting tocilizumab treatment
Exclusion criteria
* Treatment with any investigational agent within 4 weeks or 5 half-lives before tocilizumab * Continuous or regular treatment with oral corticosteroids for any indication other than RA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants Who Are Able to Discontinue Use of Glucocorticoid without Loss of Disease Control According to Disease Activity Score Based on 28 Joints (DAS28) | Week 52 |
| Percentage of Participants Who Are Able to Reduce Use of Glucocorticoid by 50 Percent (%) or More without Loss of Disease Control According to DAS28 | Week 52 |
| Percentage of Participants by Reason for Glucocorticoid Dose Modification | Baseline up to Week 52 |
Secondary
| Measure | Time frame |
|---|---|
| Time to First Glucocorticoid Dose Reduction | Baseline up to Week 52 |
| Time to Glucocorticoid Discontinuation | Baseline up to Week 52 |
| Percentage of Participants in Remission According to DAS28 with Glucocorticoid Dose Reduction | Baseline up to Week 52 |
| Percentage of Participants in Remission According to DAS28 with Glucocorticoid Dose Reduction of At Least 25%, 50%, or 75% | Baseline up to Week 52 |
| Percentage of Participants in Remission According to DAS28 Who Discontinued Glucocorticoids | Baseline up to Week 52 |
| Percentage of Participants with Low Disease Activity (LDA) According to DAS28 with Glucocorticoid Dose Reduction | Baseline up to Week 52 |
| Glucocorticoid Dose | Baseline; Weeks 24 and 52 |
| Percentage of Participants with LDA According to DAS28 Who Discontinued Glucocorticoids | Baseline up to Week 52 |
| Glucocorticoid Dose among Participants in Remission According to DAS28 | Baseline up to Week 52 |
| Glucocorticoid Dose among Participants with LDA According to DAS28 | Baseline up to Week 52 |
| Correlation between DAS28 Score and Glucocorticoid Dose | Baseline up to Week 52 |
| Percentage of Participants with Adverse Events | Baseline up to Week 52 |
| Percentage of Participants with LDA According to DAS28 with Glucocorticoid Dose Reduction of At Least 25%, 50%, or 75% | Baseline up to Week 52 |
| Percentage of Participants Who Are Able to Reduce Use of Glucocorticoid by 25%, 50%, 75%, or 100% | Weeks 24 and 52 |
| Percentage of Participants in Need of Glucocorticoid Dose Increase by 25%, 50%, 75%, or 100% | Weeks 24 and 52 |
Countries
Belgium
Outcome results
None listed